Evidence map›Paper›PMID 33837646›Full record

ReviewJournal of cellular and molecular medicine2021

Insights into the regulatory role of Plexin D1 signalling in cardiovascular development and diseases.

Yi-Fei Zhang, Yu Zhang, Dong-Dong Jia, Hong-Yu Yang, Meng-Die Cheng, Wen-Xiu Zhu, Hui Xin, Pei-Feng Li, Yin-Feng Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Vascular mechanotransduction.Physiological reviews · 2023
    Review
  9. Article
  10. An X-linkedTranslational pediatrics · 2022
    Article
  11. Review
  12. Review
  13. Common Polymorphisms in theFrontiers in cardiovascular medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yi-Fei ZhangInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Yu ZhangInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Dong-Dong JiaInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Hong-Yu YangInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Meng-Die ChengDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wen-Xiu ZhuDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hui XinDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Pei-Feng LiInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Yin-Feng ZhangInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.ORCID 0000-0003-2457-7712
Qingdao University · CN

Funding

Hubei Key Laboratory of Environmental and Health Effects of Persistent Toxic Substances PTS2019-05National Natural Science Foundation of China 22006084People's Livelihood Science and Technology Project of Qingdao 18-6-1-63-nshQingdao Applied Basic Research Project 19-6-2-49-cg
6 · The paper itself

Abstract

Plexin D1 (PLXND1), which was previously thought to mediate semaphorin signalling, belongs to the Plexin family of transmembrane proteins. PLXND1 cooperates mostly with the coreceptor neuropilin and participates in many aspects of axonal guidance. PLXND1 can also act as both a tumour promoter and a tumour suppressor. Emerging evidence suggests that mutations in PLXND1 or Semaphorin 3E, the canonical ligand of PLXND1, can lead to serious cardiovascular diseases, such as congenital heart defects, CHARGE syndrome and systemic sclerosis. Upon ligand binding, PLXND1 can act as a GTPase-activating protein (GAP) and modulate integrin-mediated cell adhesion, cytoskeletal dynamics and cell migration. These effects may play regulatory roles in the development of the cardiovascular system and disease. The cardiovascular effects of PLXND1 signalling have gradually been elucidated. PLXND1 was recently shown to detect physical forces and translate them into intracellular biochemical signals in the context of atherosclerosis. Therefore, the role of PLXND1 in cardiovascular development and diseases is gaining research interest because of its potential as a biomarker and therapeutic target. In this review, we describe the cardiac effects, vascular effects and possible molecular mechanisms of PLXND1 signalling.

Indexed as

Signal TransductionAnimalsCardiovascular DiseasesHumansIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsPLXND1 protein, humanPlxnd1 protein, mouseangiogenesiscardiovasculardevelopmentdiseasePlexin D1signalling

Identifiers

PMID33837646
PMCPMC8093976
OpenAlexW3149632753

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.